Table 3. Cycle 2: Univariate analysis of severe neutropeniaa.
| Variable | Severe neutropenia (30%) | p-value | |
| No (n = 45) | Yes (n = 19) | ||
| M dose, mg/kg (mean ± SD) | 0.36±0.12 | 0.51±0.13 | |
| Median (range) | 0.34 (0.04–0.57) | 0.52 (0.26–0.71) | |
| ≤0.50 | 40 (89) | 7 (37) | <0.001c |
| >0.50 | 5 (11) | 12 (63) | |
| ≤0.40 | 31 (69%) | 4 (21%) | 0.01c |
| >0.40 | 14 (31%) | 15 (79%) | |
| Chemotherapy agents | 0.26 | ||
| M only | 22 (49%) | 9 (47%) | |
| M+ T/C | 20 (44%) | 6 (32%) | |
| M+ T + C | 3 (7%) | 4 (21%) | |
| Prior treatmentb | 0.13 | ||
| No | 22 (51%) | 5 (29%) | |
| Yes | 21 (49%) | 12 (71%) | |
| Cycle 1 grade 3 or 4 neutropenia | 0.66 | ||
| No | 27 (60%) | 9 (47%) | |
| No record | 10 (22%) | 5 (26%) | |
| Yes | 8 (18%) | 5 (26%) | |
M: melphalan; T: topotecan; C: carboplatin.
a
Only one variable was associated with severe neutropenia at p≤0.05 on univariate analysis; multivariate analysis was not performed.
b
Data not available for 4 patients (2 had and 2 did not have severe neutropenia).
c
Cut-off point selection adjusted p-value.